Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 7,089 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Docetaxel, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 85 more

Conditions: Breast Cancer
Interventions: Anastrozole, Exemestane/Letrozole; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 16,989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Cancer of the Breast
Interventions: Physical Activity Intervention; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: TAS-102 tablets, TAS-102 oral solution; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Breast Cancer
Interventions: herceptin, carboplatin, docetaxel, conventional surgery, radiation therapy; Biological · Drug · Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: East Brunswick, New Jersey • Freehold, New Jersey • Hamilton, New Jersey + 5 more

Conditions: Breast Cancer Related Lymphoedema, Lymphoedema
Interventions: LYT-100 BCRL, Placebo BCRL; Drug
Lead sponsor: PureTech; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California • Maitland, Florida + 1 more

Conditions: Breast Cancer
Interventions: CBCT Scan, OBI KV Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Obesity
Interventions: Survivors RESET; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Primary Hormone Receptor Positive Breast Cancer
Interventions: Exercise Treatment, Plant-Based Diet, Physical activity, Nutrition counseling, Replication Exercise Test; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Prostate Cancer, Advanced Solid Tumors
Interventions: AZD5363, Enzalutamide, Fulvestrant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Middletown, New Jersey • Harrison, New York • New York, New York

Conditions: Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, Metastatic Triple Negative Breast Cancer
Interventions: CTLA-4 Antibody, Hypofractionated Radiotherapy; Drug · Radiation
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: HR+/HER2- Breast Cancer
Interventions: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 84
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 79 more

Conditions: Breast Cancer
Interventions: vepdegestrant, PF-07220060; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 22 more

Conditions: Breast Cancer, Cognitive Impairment
Interventions: Not listed
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years and older · Female only
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Breast Cancer
Interventions: neratinib, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Gemcitabine and Carboplatin, P276-00 along with Gemcitabine and carboplatin; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Burbank, California • La Jolla, California • Sacramento, California + 1 more

Conditions: Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
Interventions: Boserolimab, Pembrolizumab, Pemetrexed, Carboplatin, Nab-paclitaxel; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Mobile, Alabama • Sarasota, Florida • Germantown, Tennessee

Conditions: Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: sunitinib malate, paclitaxel, doxorubicin hydrochloride, cyclophosphamide, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis, flow cytometry; Drug · Biological · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 7
States / cities: Anchorage, Alaska • Tucson, Arizona • Boise, Idaho + 3 more

Conditions: Breast Cancer
Interventions: intracavitary balloon brachytherapy, intraoperative radiation therapy; Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium; Biological · Drug · Procedure + 1 more
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Brain Metastases
Interventions: Vorinostat, Radiation Therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
Interventions: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

TAC Versus TC for Adjuvant Breast Cancer

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

LYT-100 in Patients With BCRL

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study

A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Radiation Therapy in Treating Patients With Recurrent Breast Cancer

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)